Related Experiment Video

Updated: Jun 22, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

114

CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

Chunge Zhong1,2,3,4, Wen-Jie Jiang5, Yingjia Yao1,2,3

  • 1Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang, 110819, China.

Nature Communications
|July 1, 2024
PubMed

Insights

This study identifies genetic drivers of chemotherapy resistance using CRISPR screens. A key finding is targeting PLK4 can overcome distinct chemoresistance routes, offering a potential therapeutic strategy.

Area of Science:

  • Genetics
  • Cancer Biology
  • Pharmacology

Background:

  • Chemotherapy resistance is a significant obstacle in cancer treatment.
  • Understanding the genetic basis of resistance is crucial for developing effective therapies.

Purpose of the Study:

  • To systematically identify genetic drivers of chemoresistance across various cancer types and chemotherapeutic agents.
  • To uncover shared vulnerabilities in distinct chemoresistance pathways, specifically in colorectal cancer.
  • To identify novel therapeutic targets to overcome chemoresistance.

Main Methods:

  • Performed 30 genome-scale CRISPR knockout screens across multiple cancer cell lines with seven chemotherapeutic agents.
  • Conducted 26 second-round CRISPR screens using a druggable gene library to identify consensus vulnerabilities in oxaliplatin and irinotecan resistance.
  • Utilized genetic ablation and pharmacological inhibition to validate therapeutic targets.

Main Results:

  • Chemoresistance genes identified were condition-specific due to genetic background and drug mechanisms, revealing heterogeneous resistance routes.
  • Discovered shared vulnerabilities in evolutionarily distinct chemoresistance to oxaliplatin and irinotecan in colorectal cancer.
  • Identified PLK4 as a druggable target that can overcome oxaliplatin resistance in various models.

Conclusions:

  • Genetic drivers of chemoresistance are diverse, but common vulnerabilities exist.
  • Targeting PLK4 presents a promising single-agent strategy to combat evolutionarily distinct chemoresistance.
  • The study provides valuable resources, biomarkers, and therapeutic strategies for overcoming chemoresistance.

More Related Videos

Pooled CRISPR-Based Genetic Screens in Mammalian Cells00:09

Pooled CRISPR-Based Genetic Screens in Mammalian Cells

Published on: September 4, 2019

21.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.4K